Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update
Globe Newswire•06/08/2026•07:00 ET
0
Whiz Insights
- FHD-909 (LY4050784) Phase 1 dose-escalation trial advancing as planned with non-small cell lung cancer (NSCLC) as the primary target population
- Selective EP300 degraders with potential to treat multiple myeloma and other hematological malignancies advancing; IND targeted in 2027
Get started
Create a free account to read the full story.